Qun Tang

Prof. Qun Tang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
FZFeng Zhou
Feng Zhou
GZGuo Dong Zhang
Guo Dong Zhang
YTYang Tan
Yang Tan
SHShi An Hu
Shi An Hu
QTQun Tang
Qun Tang
PPPg pei
Pg pei
Inflammatory bowel disease (IBD) is a chronic gastrointestinal inflammatory disease that involves host genetics, the microbiome, and inflammatory responses. The current consensus is that the disruption of the intestinal mucosal barrier is the core pathogenesis of IBD, including intestinal microbial factors, abnormal immune responses, and impaired intestinal mucosal barrier. Cumulative data show that nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) are dominant mediators in maintaining the homeostasis of the intestinal mucosal barrier, which play critical roles in sensing the commensal microbiota, maintaining homeostasis, and regulating intestinal inflammation. Blocking NLRs inflammasome activation by botanicals may be a promising way to prevent IBD progression. In this review, we systematically introduce the multiple roles of NLRs in regulating intestinal mucosal barrier homeostasis and focus on summarizing the activities and potential mechanisms of natural products against IBD. Aiming to propose new directions on the pathogenesis and precise treatment of IBD

1 July 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
HWHui Wang
Hui Wang
SCShuang-Shuang Chen
Shuang-Shuang Chen
YZYong-Xian Zhang
Yong-Xian Zhang
HGHai-Bo Gao
Hai-Bo Gao
BMBin Meng
Bin Meng
QTQun Tang
Qun Tang
Background: Renal fibrosis (RF) is the final outcome of chronic kidney disease (CKD), which can be triggered by various factors. Liuwei Dihuang Decoction (LWDHD) has been clinically established as an effective treatment for CKD, demonstrating anti-inflammatory, antioxidant, and antifibrotic effects. However, the specific molecular mechanisms underlying the therapeutic effectiveness of LWDHD remain unknown. Aim: Prediction of key active ingredients, targets, and mechanistic pathways of LWDHD in RF treatment. Materials and Methods: The bioactive components of LWDHD were identified and quantified using ultra-performance liquid chromatography-tandem quadrupole mass spectrometry (UHPLC-MS/MS). A network pharmacology approach was employed to predict the key targets of these bioactive components. A rat model of renal tubulointerstitial fibrosis was created through unilateral ureteral obstruction (UUO). Rats were divided into six groups: sham operation, UUO, low-dose LWDHD (LW-L), medium-dose LWDHD (LW-M), high-dose LWDHD (LW-H), and enalapril group. Continuous gavage of treatments was administered for 2 weeks. The renal tissues were histopathologically assessed, including HE, Masson’s trichrome, and Sirius red staining, immunohistochemistry, co-staining and Western blot analysis to evaluate the effects of LWDHD on renal fibrosis. Transforming growth factor beta-1 (TGF-β 1) was employed to stimulate endothelial-mesenchymal transition (EndMT) in EA.hy926 cells. The inhibitory effect of LWDHD on EndMT was validated through cellular morphology observations, Western blotting, and immunofluorescence assays. Results: LWDHD showed promise as a therapeutic agent by alleviating renal pathological injury and lowering collagen fiber accumulation. It enhanced Sirt1 expression while inhibiting the Wnt/β-catenin signaling pathway. Moreover, LWDHD increased the levels of the endothelial marker CD31 and decreased the expression of fibrosis-associated proteins, such as α-smooth muscle actin (α-SMA) and vimentin, thereby mitigating renal fibrosis. Conclusion: LWDHD has the potential to alleviate renal fibrosis, possibly through the upregulation of Sirt1, which inhibits the Wnt/β-catenin signaling pathway and thereby reduces EndMT.